# MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment

> **NCT06177028** · PHASE2 · NOT_YET_RECRUITING · sponsor: **St. Joseph's Hospital and Medical Center, Phoenix** · enrollment: 45 (estimated)

## Conditions studied

- Cognitive Impairment, Mild
- Cognitive Dysfunction
- Amyloid Plaque
- Neurodegenerative Disease, Hereditary
- Inflammation, Brain

## Interventions

- **DRUG:** Lenalidomide 10 mg

## Key facts

- **NCT ID:** NCT06177028
- **Lead sponsor:** St. Joseph's Hospital and Medical Center, Phoenix
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2026-01-02
- **Final completion:** 2027-01-02
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06177028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06177028, "MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06177028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*